We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| New Generation Consumer Group Inc (PK) | USOTC:NGCG | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0011 | 0.0011 | 0.0012 | 0.0011 | 0.0011 | 0.0011 | 60,000 | 13:01:04 |
October 16, 2020 -- via Seeking Alpha -- By: Manshi Mamtora, CFA, SA News Editor
- PAO Group (OTCPK:PAOG +10.5%) anticipates entering into an agreement with a contract research organization or CRO within the next two weeks.
- The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (or COPD) toward FDA approval.
- PAOG acquired RespRx from Kali-Extracts (OTCPK:KALY -8.3%), which is a cannabis treatment under development for COPD derived from a patented cannabis extraction method.
- Related: PURA in management takeover deal with PAO Group.
Press Release
Other stocks on the move: AITX, OZSC, and NGCG
Source: https://seekingalpha.com/news/3622545-paog-to-soon-finalize-cro-engagement-for-cannabis-drug
1 Year New Generation Consumer (PK) Chart |
1 Month New Generation Consumer (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
